Study of Antigens Induced by DTIC in Mouse Leukemia Cells
Author Information
Author(s): O. Marelli, P. Franco, G. Cantil, L. Ricci, N. Prandoni, A. Nicolin, H. Festenstein
Primary Institution: Department of Pharmacology, School of Medicine, Milan; Department of Pharmacology, National Cancer Institute, Genoa; Transplantation Immunology Unit, Department of Immunology, London Hospital Medical College
Hypothesis
Does DTIC treatment induce new antigens on tumor cells?
Conclusion
DTIC treatment induces new antigens on tumor cells that can elicit an immune response.
Supporting Evidence
- DTIC-treated subclones were rejected by syngeneic hosts but grew in immunosuppressed hosts.
- Three specific antigens were identified in the study.
- DTIC treatment did not modify pre-existing histocompatibility antigens.
Takeaway
The study shows that a cancer drug called DTIC can make tumor cells show new markers that help the immune system recognize and attack them.
Methodology
Mouse leukemia L1210 cells were cloned and treated with DTIC, followed by analysis of immune response in mice.
Limitations
The exact mechanism of antigen modification by DTIC remains unclear.
Participant Demographics
CD2F1 mice of both sexes, aged 6-8 weeks.
Want to read the original?
Access the complete publication on the publisher's website